Company Description
Alamar Biosciences is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis.
Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.
Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics.
We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries.
Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs.
| Country | United States |
| Founded | 2018 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 222 |
| CEO | Yuling Luo, Ph.D. |
Contact Details
Address: 47071 Bayside Parkway Fremont, CA 94538 United States | |
| Phone | (510) 626-9888 |
| Website | alamarbio.com |
Stock Details
| Ticker Symbol | ALMR |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 2104204 |
| Employer ID | 36-4899036 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Yuling Luo, Ph.D. | Founder, Chief Executive Officer and Chairman |
| Timothy “Tod” White | President |
| Justin McAnear | Chief Financial Officer |
| Shiping “Steve” Chen, Ph.D. | Founder, Chief Operating Officer and Director |
| Rebecca Chambers | Director |
| Nicholas Naclerio, Ph.D. | Director |
| Ian W. Ratcliffe | Director |
| Frank R. Witney, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 12, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 17, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 9, 2026 | DRS | [Cover] Draft Registration Statement |